Feasibility Trial of ValenTx Endo Bypass System

Obesity Clinical Trial

Official title:

A Single Center Feasibility Trial of the Safety and Efficacy of the ValenTx Endo Bypass System in Obese Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01207804
• Other study ID #: FIM
• Status: Completed
• Phase: N/A
• First received: September 21, 2010
• Last updated: March 15, 2016
• Start date: August 2008
• Est. completion date: May 2009

Study information

• Verified date: March 2016
• Source: ValenTx, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Mexico: Ethics CommitteeMexico: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to provide initial clinical data to support the feasibility of use of the ValenTx Endo Bypass system in enhancing weight loss and co-morbidity resolution in morbidly obese patients.

Description:

This is a single center open label feasibility study to evaluate the safety, efficacy and performance of the ValenTx Endo Bypass system.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: May 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Male or female between 18 and 55 years of age

• >=35 kg/m2 and <= 50 kg/m2, with or without comorbid conditions(s).

• Documented failure with non-surgical weight loss methods

• Willing to comply with study procedures and visit schedule

• Willing and able to provide Informed Consent

Exclusion Criteria:

• Pregnancy or intention of becoming pregnant within the study duration.

• Endoscopic lesions such as important hiatal hernia, gastric or duodenal ulcer, atresias or stenosis, polyps of the stomach.

• Subject with potential upper gastrointestinal bleeding such as esophageal or gastric varices, Mallory-Weis syndrome or congenital or acquired intestinal telangiectasia.

• Past history of esophageal or gastric/GI surgery, obstruction, adhesive peritonitis, or large hiatal hernia (> 3 cm).

• IBS, unexplained intermittent vomiting, severe abdominal pain or chronic constipation within 60 days of study day 1

• Unexplained anaemia, Pancreatitis, Portal hypertension, Esophagitis or Barrett's esophagus, known gallstones or anomalies of the GI tract

• Any bodily infections within 30 days of study day 1.

• Prolonged steroid use

• Hep C or HIV positive

• Known allergies to any of the device materials

• Use of weight loss medication or an investigational drug or device within 2 months prior to enrolment and throughout the study period.

• Recent or ongoing cancer, history of severe renal, hepatic, cardiovascular or pulmonary disease or transplants

• Inability to tolerate anti-inflammatory medications

• Evidence of psychiatric problems or dietary habits that would contraindicate study treatment;

• Active drug or alcohol addiction within 12 months of enrolment and throughout the study duration.

• Prior history of inflammatory diseases of the GI tract, (e.g., esophagitis, varices, gastric or duodenal ulceration, or Crohn's disease; congenital or acquired GI anomalies, e.g., bowel strictures)

• Ongoing treatment with anticoagulants, steroids, aspirin, NSAIDs, or other gastric irritants within 1 month prior to enrollment and throughout the study period.

• Participation in previous (within 60 days of study day 1) or ongoing clinical trial or current or past usage (within 60 days of study day 1) of investigation drug or device.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Obesity

Intervention

Device:
• ValenTx Endo Bypass System
Patient is implanted with device and followed for 12 weeks

Locations

Country	Name	City	State
Mexico	Hospital San Jose Tec de Monterrey	Monterrey

Sponsors (1)

Lead Sponsor	Collaborator
ValenTx, Inc.

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Device-related adverse events		12 weeks	Yes
Secondary	Device performance		12 weeks	Yes